ENANTA PHARMACEUTICALS INC

ENTA · Nasdaq · SIC 2834: Pharmaceutical Preparations
187
SEC Filings

Business Summary

PART I ITEM 1. B USINESS BUSINESS Overview We are a biotechnology company that uses our robust, chemistry-driven approach and drug discovery capabilities to discover and develop small molecule drugs for virology and immunology indications. Virology: We discovered glecaprevir, the second of two antiviral protease inhibitors developed through our collaboration with AbbVie for the treatment of acute or chronic infection with hepatitis C virus, or HCV. Glecaprevir is co-formulated as part of AbbVies...

Next Earnings

Q2 FY2026 — expected 2026-09-21

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionENTAdiscussed_in_filing Healthcare & Bio
topic_mentionENTAdiscussed_in_filing Healthcare & Bio
topic_mentionENTAdiscussed_in_filing Healthcare & Bio
topic_mentionENTAdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-11-192025-09-300001193125-25-288121EDGAR73K words
2024-11-272024-09-300000950170-24-131260EDGAR—
2023-11-222023-09-300000950170-23-065884EDGAR—
2022-11-232022-09-300000950170-22-025667EDGAR—
2021-11-242021-09-300000950170-21-004895EDGAR—
2020-11-252020-09-300001564590-20-055233EDGAR—
2019-11-272019-09-300001564590-19-044729EDGAR—
2018-11-292018-09-300001564590-18-030275EDGAR—
2017-12-112017-09-300001564590-17-024794EDGAR—
2016-12-092016-09-300001193125-16-789660EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-02-112025-12-310001193125-26-046502EDGAR17K words
2025-08-132025-06-300001193125-25-179795EDGAR—
2025-05-142025-03-310000950170-25-071340EDGAR—
2025-02-122024-12-310000950170-25-018810EDGAR—
2024-08-072024-06-300000950170-24-092714EDGAR—
2024-05-082024-03-310000950170-24-055581EDGAR—
2024-02-082023-12-310000950170-24-012796EDGAR—
2023-08-082023-06-300000950170-23-039754EDGAR—
2023-05-092023-03-310000950170-23-019842EDGAR—
2023-02-082022-12-310000950170-23-002134EDGAR—
2022-08-082022-06-300000950170-22-015515EDGAR—
2022-05-092022-03-310000950170-22-008483EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-260001193125-26-125113EDGAR1K words
2026-03-120001193125-26-104109EDGAR—
2026-02-090001193125-26-042812EDGAR—
2025-11-170001193125-25-284633EDGAR—
2025-10-010001193125-25-226828EDGAR—
2025-09-290001193125-25-221791EDGAR—
2025-09-290001193125-25-221527EDGAR—
2025-08-270001193125-25-189691EDGAR—
2025-08-200001193125-25-183719EDGAR—
2025-08-110001193125-25-177941EDGAR—

187 total filings indexed. 155 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001177648
TickerENTA
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: a3783b50498a9b0583c7c968a73e8d70b0fac1d8447706440b067cae00489218
parent: 7a1a91260c8e634cbdb140421c935243eab01aa01c0d8d6543b0d0aec33bad31
content hash: e0bbb9d0cd1d827dca2957d126c6cd3e550208b3624fdf20304457b7b0cefac9
signed: 2026-04-13T04:44:52.229Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf